This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://digital.ahrq.gov/contact-us. Let us know the nature of the problem, the Web address of what you want, and your contact information.
Please go to digital.ahrq.gov for current information.

Assessing the validity of national quality measures for coronary artery disease using an electronic health record

Nationally endorsed, clinical performance measures are available that allow for quality reporting using electronic health records (EHRs), but how well they reflect actual quality of care has not been studied. We performed a retrospective electronic medical chart review comparing automated measurement with a 2-step process of automated measurement supplemented by review of free-text notes for apparent quality failures for all patients with CAD from a large internal medicine practice using a commercial EHR. There were 7 performance measures included the following: antiplatelet drug, lipid-lowering drug, beta-blocker following myocardial infarction, blood pressure measurement, lipid measurement, low-density lipoprotein cholesterol control, and angiotensin-converting enzyme inhibitor or angiotensin receptor blocker for patients with diabetes mellitus or left ventricular systolic dysfunction. Profiling the quality of outpatient CAD care using data from an EHR has significant limitations. Changes in how data are routinely recorded in an EHR are needed to improve the accuracy of this type of quality measurement. Validity testing in different settings is required.

Author(s)
Persell SD, Wright JM, Thompson JA, Kmetik KS, Baker DW
Journal
Arch Intern Med
Publication Year
2006
Publication Month
Nov
Volume
166
Issue
20
Page Number
2272-7
The information on this page is archived and provided for reference purposes only.